4-(2-氨基乙氧基)-3-甲氧基苯酚 | 1076198-80-5

• 物质功能分类: 有机原料 - 醇、酚、酚醇类化合物及衍生物 - 酚及其卤化、磺化、硝化或亚硝化衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 4-(2-氨基乙氧基)-3-甲氧基苯酚
• 英文名称: 4-(2-Aminoethoxy)-3-methoxyphenol
• CAS: 1076198-80-5
• 化学式: C₉H₁₃NO₃
• mdl: MFCD09753578
• 分子量: 183.207
• InChiKey: ZJWDKSXPRPBBIJ-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于甲醇、二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  64.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(2-氨基乙氧基)-3-甲氧基苯酚 、 4-环氧丙烷氧基咔唑 在 lithium bromide 作用下， 以 异丙醇 为溶剂， 反应 12.0h， 以180 mg的产率得到4-[2-[[3-(9H-咔唑-4-基氧基)-2-羟基丙基]氨基]乙氧基]-3-甲氧基-苯酚
  参考文献：
  名称：

  Suppression of store overload-induced calcium release by hydroxylated metabolites of carvedilol

  摘要：

  Carvedilol is a drug widely used in the treatment of heart failure and associated cardiac arrhythmias. A unique action of carvedilol is its suppression of store overload-induced calcium release (SOICR) through the cardiac ryanodine receptor (RyR2), which can trigger ventricular arrhythmias. Since the effects of carvedilol metabolites on SOICR have not yet been investigated, three carvedilol metabolites hydroxylated at the 3-, 4' and 5'-positions were synthesized and assayed for SOICR inhibition in mutant HEK 293 cells expressing the RyR2 mutant R4496C. This cell line is especially prone to SOICR and calcium release through the defective RyR2 channel was measured with a calcium-sensitive fluorescent dye. These results revealed that the 3- and 4'-hydroxy derivatives are slightly more effective than carvedilol in suppressing SOICR, while the 5'-analog proved slightly less active. Metabolic deactivation of carvedilol via these hydroxylation pathways is therefore insignificant. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.11.008
• 作为产物：
  描述：

  4-(2-bromoethoxy)-3-methoxyphenol 在 ammonium hydroxide 作用下， 以 水 为溶剂， 反应 4.0h， 生成 4-(2-氨基乙氧基)-3-甲氧基苯酚
  参考文献：
  名称：

  Suppression of store overload-induced calcium release by hydroxylated metabolites of carvedilol

  摘要：

  Carvedilol is a drug widely used in the treatment of heart failure and associated cardiac arrhythmias. A unique action of carvedilol is its suppression of store overload-induced calcium release (SOICR) through the cardiac ryanodine receptor (RyR2), which can trigger ventricular arrhythmias. Since the effects of carvedilol metabolites on SOICR have not yet been investigated, three carvedilol metabolites hydroxylated at the 3-, 4' and 5'-positions were synthesized and assayed for SOICR inhibition in mutant HEK 293 cells expressing the RyR2 mutant R4496C. This cell line is especially prone to SOICR and calcium release through the defective RyR2 channel was measured with a calcium-sensitive fluorescent dye. These results revealed that the 3- and 4'-hydroxy derivatives are slightly more effective than carvedilol in suppressing SOICR, while the 5'-analog proved slightly less active. Metabolic deactivation of carvedilol via these hydroxylation pathways is therefore insignificant. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.11.008

文献信息

• DE2843016
  申请人：——

  公开号：——

  公开（公告）日：——